Hepion Pharmaceuticals IncNASDAQ:HEPANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6990
- TODAY'S CHANGE (%)0.0090 (1.3043%)
- Bid / Lots0.6625/ 1
- Ask / Lots0.6990/ 17
- Open / Previous Close0.7100 / 0.6900
- Day Range
- 52 Week Range
- Volume17,887
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HEPA |
|---|---|---|
| 09:32 ET | 137 | 0.71 |
| 09:33 ET | 136 | 0.69 |
| 09:35 ET | 300 | 0.6616 |
| 09:42 ET | 150 | 0.6621 |
| 11:57 ET | 3893 | 0.6625 |
| 12:01 ET | 1571 | 0.6625 |
| 12:06 ET | 10200 | 0.6899 |
| 12:19 ET | 100 | 0.67 |
| 02:32 ET | 224 | 0.699 |
Nov 11, 2024
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger, from 8:00AM ET on Monday Nov 11, 2024 by Dow Jones
8:00AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Hepion Pharmaceuticals Inc | 4.8M | -0.2x | --- |
Purple Biotech Ltd | 4.8M | 0.0x | --- |
Bionomics Ltd | 4.8M | 0.0x | --- |
Raphael Pharmaceutical Inc | 4.9M | -4.9x | --- |
Check Cap Ltd | 4.7M | -0.3x | --- |
Portage Biotech Inc | 4.7M | -0.1x | --- |
Company Information
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.
Contact Information
- Headquarters
- 399 Thornall StEDISON, NJ, United States 08837-2236
- Phone
- 732-902-4000
- Fax
- 732-902-4100
Executives
- Executive Chairman of the Board, Interim Chief Executive Officer, Interim Chief Financial Officer
- John Brancaccio
- Independent Director
- Timothy Block
- Independent Director
- Kaouthar Lbiati
- Independent Director
- Michael Purcell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 7.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.65 |
EPS | $-4.47 |
Book Value | $1.51 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
